Married | Real estate agent | 2 active children
Hypothetical patient portrayal. Individual results may vary.
Diagnostic Criteria & Patient Profile
Frustrated. Determined. Ready. Barbara wants to make a change in her MDD story.
To be diagnosed with MDD, a patient must have 5 or more of the following symptoms nearly every day* during the same 2-week period and represent a change from previous functioning. At least 1 symptom must be either depressed mood or loss of interest/pleasure.
1. Depressed mood most of the day
2. Loss of interest/pleasure in almost all activities most of the day
3. Significant change in weight or appetite
4. Insomnia or hypersomnia
5. Psychomotor agitation/retardation
6. Loss of energy or fatigue
7. Feelings of worthlessness or excessive or inappropriate guilt
8. Difficulty concentrating or indecisiveness
9. Recurrent suicidal thoughts or actions or recurrent thoughts of death
Do not include symptoms attributable to another medical condition.
Diagnosis should be based on a complete history and evaluation of the patient. View printable PHQ-9 screener.
*”Nearly every day” does not apply to symptom 3 (weight gain) and symptom 9.15
These are not the complete diagnostic criteria. DSM-5 is a registered trademark of the American Psychiatric Association.
Barbara struggles to manage her MDD symptoms. She’s ready to do whatever it takes to get the relief she wants. This is a turning point in her story.
Not a complete list of symptoms. Having these symptoms does not necessarily mean a patient has MDD. Diagnosis should be based on full DSM-5® diagnostic criteria for MDD. Patients should be individually assessed for MDD with appropriate evaluation, management, and follow-up. Medication may not be appropriate for all patients with MDD. Individual results may vary.
DSM-5 is a registered trademark of the American Psychiatric Association.
Tools for your patients and practice
Support for
your patients
We’re here to help your eligible patients get the treatment you prescribe.
Telling patients
about telehealth
As telehealth visits become more common, it’s important to have helpful resources for you and your patient.
Patient coverage
in your area
Find out about formulary coverage in your area for TRINTELLIX.
Helping patients access savings info and support
Discover resources that may help your patients with savings and more.
Prescription
savings for your
eligible patients
Find out about savings and support offered through tAccess by reading the Savings Card brochure.
Long-term
clinical data
Results from multiple clinical studies of TRINTELLIX.
Offering
patients once
daily dosing
Learning about dosage amounts and drug interactions.
Request a
rep visit
Connect with a TRINTELLIX representative.
Patient profile
Learn more about a patient
living with MDD.
Safety profile
See how the safety profile fits in the story.
WARNING: SUICIDAL THOUGHTS & BEHAVIORS
CONTRAINDICATIONS
WARNINGS AND PRECAUTIONS
ADVERSE REACTIONS
The most commonly observed adverse reactions for TRINTELLIX in 6- to 8-week placebo-controlled studies (incidence ≥5% and at least twice the rate of placebo) were: nausea, constipation, and vomiting.
DRUG INTERACTIONS
Concomitant administration of TRINTELLIX and strong CYP2D6 inhibitors or strong CYP inducers may require a dose adjustment of TRINTELLIX.
PREGNANCY
Exposure to serotonergic antidepressants, including TRINTELLIX, in late pregnancy may increase the risk for neonatal complications requiring prolonged hospitalization, respiratory support, and tube feeding, and/or persistent pulmonary hypertension of the newborn (PPHN). Monitor neonates who were exposed to TRINTELLIX in the third trimester for PPHN and drug discontinuation syndrome.
TRINTELLIX is indicated for the treatment of Major Depressive Disorder (MDD) in adults.
Please click for Full Prescribing Information.
There is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to antidepressants during pregnancy. Healthcare providers are encouraged to register patients by calling the National Pregnancy Registry for Antidepressants at 1-844-405-6185 or visiting online at
WARNING: SUICIDAL THOUGHTS & BEHAVIORS
CONTRAINDICATIONS
WARNINGS AND PRECAUTIONS
ADVERSE REACTIONS
The most commonly observed adverse reactions for TRINTELLIX in 6- to 8-week placebo-controlled studies (incidence ≥5% and at least twice the rate of placebo) were: nausea, constipation, and vomiting.
DRUG INTERACTIONS
Concomitant administration of TRINTELLIX and strong CYP2D6 inhibitors or strong CYP inducers may require a dose adjustment of TRINTELLIX.
PREGNANCY
Exposure to serotonergic antidepressants, including TRINTELLIX, in late pregnancy may increase the risk for neonatal complications requiring prolonged hospitalization, respiratory support, and tube feeding, and/or persistent pulmonary hypertension of the newborn (PPHN). Monitor neonates who were exposed to TRINTELLIX in the third trimester for PPHN and drug discontinuation syndrome.
TRINTELLIX is indicated for the treatment of Major Depressive Disorder (MDD) in adults.
Please click for Full Prescribing Information.
There is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to antidepressants during pregnancy. Healthcare providers are encouraged to register patients by calling the National Pregnancy Registry for Antidepressants at 1-844-405-6185 or visiting online at